|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12345678910111213...4647» |
- | dexmedetomidine / Generic mfg.
Surgery: Use of Dexmedetomidine in Children Undergoing Oral Maxillofacial Surgery to Decrease Emergence Delirium (clinicaltrials.gov) - May 5, 2017
P4, N=0, Withdrawn, Sponsor: Shanghai 9th People's Hospital
N=90 --> 0
- | Trial completion, Trial primary completion date: ProsKuopio: Computational Tools for Early Diagnosis of Memory Disorders (clinicaltrials.gov) - May 3, 2017
P=N/A, N=126, Completed, Sponsor: University of Eastern Finland
N=90 --> 0 Enrolling by invitation --> Completed | Trial primary completion date: Jun 2016 --> Apr 2017
- | Trial completion, Phase classification: VENUS: Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus (clinicaltrials.gov) - May 3, 2017
P3, N=300, Completed, Sponsor: University of Science Malaysia
Enrolling by invitation --> Completed | Trial primary completion date: Jun 2016 --> Apr 2017 Active, not recruiting --> Completed | Phase classification: P4 --> P3
- | Trial completion: Implementation of a Multicomponent Intervention to Prevent Physical Restraints in Nursing Home Residents (IMPRINT) (clinicaltrials.gov) - May 3, 2017
P=N/A, N=10800, Completed, Sponsor: University of Luebeck
Active, not recruiting --> Completed | Phase classification: P4 --> P3 Active, not recruiting --> Completed
- | Trial primary completion date: The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy (clinicaltrials.gov) - May 2, 2017
P=N/A, N=280, Recruiting, Sponsor: Shanghai Mental Health Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Sep 2017
- Trial primary completion date: Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - May 2, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: University at Buffalo
Trial primary completion date: Dec 2015 --> Sep 2017 Trial primary completion date: Oct 2016 --> Sep 2018
- | Biomarker, Trial completion, Trial primary completion date: Down Syndrome Biomarker Initiative (DSBI) (clinicaltrials.gov) - May 2, 2017
P=N/A, N=12, Completed, Sponsor: Michael Rafii
Trial primary completion date: Oct 2016 --> Sep 2018 Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Apr 2017
- | Trial completion: Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) (clinicaltrials.gov) - May 2, 2017
P=N/A, N=710, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Apr 2017 Recruiting --> Completed
- | Trial completion, Trial primary completion date: Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use. (clinicaltrials.gov) - May 2, 2017
P=N/A, N=100, Completed, Sponsor: Rambam Health Care Campus
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2017
- | Enrollment change, Trial termination, Trial primary completion date: Study to Evaluate Coconut Oil for Alzheimer's Disease (clinicaltrials.gov) - Apr 28, 2017
P2/3, N=21, Terminated, Sponsor: University of South Florida
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2017 N=65 --> 21 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Feb 2017; Funding limitations and enrollment was too low.
- | verubecestat (MK-8931) / Merck (MSD)
Trial termination: EPOCH: An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) (clinicaltrials.gov) - Apr 27, 2017
P2/3, N=2210, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=65 --> 21 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Feb 2017; Funding limitations and enrollment was too low. Active, not recruiting --> Terminated
- divalproex sodium XR / Generic mfg., quetiapine / Generic mfg.
Trial termination: Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia (clinicaltrials.gov) - Apr 27, 2017
P3, N=20, Terminated, Sponsor: Tuscaloosa Research & Education Advancement Corporation
Active, not recruiting --> Terminated Completed --> Terminated; Investigator closed study and left VAMC.
- | Phase classification, Trial primary completion date: The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly (clinicaltrials.gov) - Apr 26, 2017
P, N=44, Completed, Sponsor: Tufts University
Completed --> Terminated; Investigator closed study and left VAMC. Phase classification: P=N/A --> P | Trial primary completion date: Jul 2014 --> Aug 2015
- | metformin / Generic mfg.
Biomarker, Trial completion: Effect of Insulin Sensitizer Metformin on AD Biomarkers (clinicaltrials.gov) - Apr 26, 2017
P2, N=30, Completed, Sponsor: University of Pennsylvania
Phase classification: P=N/A --> P | Trial primary completion date: Jul 2014 --> Aug 2015 Recruiting --> Completed
- | Trial primary completion date: Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment (clinicaltrials.gov) - Apr 25, 2017
P3, N=200, Active, not recruiting, Sponsor: Thomas Jefferson University
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- | Phase classification: Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine (clinicaltrials.gov) - Apr 25, 2017
P1, N=10, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2016 --> Dec 2017 Phase classification: P=N/A --> P1
- | Biomarker, Trial completion, Trial primary completion date: PACE-2: Piedmont Aging, Cognition & Exercise Study-2 (clinicaltrials.gov) - Apr 21, 2017
P=N/A, N=33, Completed, Sponsor: Wake Forest University
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2017
- | amisulpride / Generic mfg.
Enrollment change, Trial termination: Optimisation of Antipsychotic Drug Use in Older People (clinicaltrials.gov) - Apr 19, 2017
P4, N=64, Terminated, Sponsor: Institute of Psychiatry, London
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2017 N=120 --> 64 | Recruiting --> Terminated; Failure to recruit people with very late onset schizophrenia like psychosis
- ||| osoresnontrine (BI 409306) / Boehringer Ingelheim
Enrollment change: Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo (clinicaltrials.gov) - Apr 19, 2017
P2, N=105, Recruiting, Sponsor: Boehringer Ingelheim
N=120 --> 64 | Recruiting --> Terminated; Failure to recruit people with very late onset schizophrenia like psychosis N=150 --> 105
- | lorazepam / Generic mfg., dexmedetomidine / Generic mfg.
Clinical: Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) (clinicaltrials.gov) - Apr 18, 2017
P4, N=49, Terminated, Sponsor: Denver Health and Hospital Authority
N=150 --> 105 Trial primary completion date: Mar 2017 --> Dec 2015
- | haloperidol / Generic mfg.
Trial completion: Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol (clinicaltrials.gov) - Apr 14, 2017
P4, N=68, Completed, Sponsor: Northeastern University
Trial primary completion date: Mar 2017 --> Dec 2015 Recruiting --> Completed
- | Trial completion, Enrollment change: Volunteers Adding Life in Dementia: VALID (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=75, Completed, Sponsor: Queen's University
Recruiting --> Completed Recruiting --> Completed | N=120 --> 75
- | Trial completion, Enrollment change: Volunteers Adding Life in Dementia (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=75, Completed, Sponsor: Queen's University
Recruiting --> Completed | N=120 --> 75 Recruiting --> Completed | N=30 --> 75
- | Trial completion, Enrollment change: PC-DATA: The Primary Care - Dementia Assessment and Treatment Algorithm (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=55, Completed, Sponsor: Queen's University
Recruiting --> Completed | N=30 --> 75 Recruiting --> Completed | N=135 --> 55
- | midazolam hydrochloride / Generic mfg.
Enrollment closed, Trial primary completion date: Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Cognitive Function (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=205, Active, not recruiting, Sponsor: Palle Toft
Recruiting --> Completed | N=135 --> 55 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jan 2017
- | Trial completion: HIAD: Hearing Instruments in Alzheimer's Disease (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=25, Completed, Sponsor: Phonak AG, Switzerland
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jan 2017 Active, not recruiting --> Completed
- | Enrollment change, Trial termination: Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients (clinicaltrials.gov) - Apr 7, 2017
P2, N=38, Terminated, Sponsor: Institut de Recherches Internationales Servier
Active, not recruiting --> Completed N=450 --> 38 | Suspended --> Terminated
- | Trial completion, Enrollment change, Trial primary completion date: Brain Aging Project--Kansas University (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=172, Completed, Sponsor: University of Kansas Medical Center
N=450 --> 38 | Suspended --> Terminated Active, not recruiting --> Completed | N=120 --> 172 | Trial primary completion date: Dec 2009 --> Aug 2009
- | donepezil / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: MUSTARDD-PD: Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease (clinicaltrials.gov) - Apr 7, 2017
P3, N=64, Terminated, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Active, not recruiting --> Completed | N=120 --> 172 | Trial primary completion date: Dec 2009 --> Aug 2009 N=500 --> 64 | Suspended --> Terminated | Trial primary completion date: May 2017 --> Sep 2014; Due to low recruitment
- | Trial completion: Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=86, Completed, Sponsor: Vanderbilt University Medical Center
N=500 --> 64 | Suspended --> Terminated | Trial primary completion date: May 2017 --> Sep 2014; Due to low recruitment Active, not recruiting --> Completed
- | olanzapine / Generic mfg., haloperidol / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=101, Completed, Sponsor: VU University Medical Center
Active, not recruiting --> Completed Recruiting --> Completed | N=300 --> 101 | Trial primary completion date: Aug 2016 --> Apr 2017
- | Enrollment closed, Phase classification: TMS-AD: Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=49, Active, not recruiting, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Completed | N=300 --> 101 | Trial primary completion date: Aug 2016 --> Apr 2017 Completed --> Active, not recruiting | Phase classification: P2 --> PN/A
- | Trial termination: Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=24, Terminated, Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD)
Completed --> Active, not recruiting | Phase classification: P2 --> PN/A Completed --> Terminated
- | rifampicin / Generic mfg., doxycycline / Generic mfg.
Biomarker, Trial completion: Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid (clinicaltrials.gov) - Apr 4, 2017
P3, N=100, Completed, Sponsor: Hamilton Health Sciences Corporation
Completed --> Terminated Active, not recruiting --> Completed
- | Enrollment closed, Trial primary completion date: A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: Palo Alto Veterans Institute for Research
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Jul 2017
- | Trial completion, Trial primary completion date: Mealtime Symptoms in Dementia (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=132, Completed, Sponsor: Duke University
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Jul 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016
- | buprenorphine transdermal / Generic mfg., paracetamol / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: DEP-PAIN-DEM: Efficacy of Pain Treatment on Depression in Patients With Dementia (clinicaltrials.gov) - Apr 4, 2017
P4, N=163, Completed, Sponsor: University of Bergen
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016 Recruiting --> Completed | N=266 --> 163 | Trial primary completion date: Jun 2015 --> Dec 2016
- | Trial completion, Trial primary completion date: AMIMAGE 2: Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=304, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed | N=266 --> 163 | Trial primary completion date: Jun 2015 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2015
- |||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Trial primary completion date: STAR Extension: Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (clinicaltrials.gov) - Apr 4, 2017
P3, N=1463, Active, not recruiting, Sponsor: H. Lundbeck A/S
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2015 Trial primary completion date: Oct 2017 --> Jul 2017
- | Trial completion: Oral Health Intervention Pilot Study for Individuals With Memory Problems (clinicaltrials.gov) - Mar 30, 2017
P=N/A, N=12, Completed, Sponsor: Duke University
Trial primary completion date: Oct 2017 --> Jul 2017 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: ATP in Alzheimer Disease (clinicaltrials.gov) - Mar 29, 2017
P2, N=20, Completed, Sponsor: Sara Varea
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Feb 2016
- ||||||| rivastigmine / Generic mfg.
Trial completion: Rivastigmine Capsules in Patients With Probable Vascular Dementia (clinicaltrials.gov) - Mar 27, 2017
P3, N=521, Completed, Sponsor: Novartis
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Feb 2016 No longer recruiting --> Completed
- | Trial completion, Trial primary completion date: Energy Metabolism and Cognitive Aging (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=62, Completed, Sponsor: University of Cincinnati
No longer recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2018 --> Dec 2016
- | Trial primary completion date: Massage Technique for Pain, Anxiety and Delirium in SAH Patients (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=50, Recruiting, Sponsor: Sara E. Hocker, M.D
Recruiting --> Completed | Trial primary completion date: Dec 2018 --> Dec 2016 Trial primary completion date: Jan 2017 --> Jan 2018
- | dexmedetomidine / Generic mfg.
HEOR: SKY-DEX: Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients? (clinicaltrials.gov) - Mar 17, 2017
P4, N=100, Completed, Sponsor: Maisonneuve-Rosemont Hospital
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Jun 2014 --> Jun 2016
- | AADvac1 / Axon Neurosci
Trial completion: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - Mar 17, 2017
P1, N=25, Completed, Sponsor: Axon Neuroscience SE
Trial primary completion date: Jun 2014 --> Jun 2016 Active, not recruiting --> Completed
- |||| verubecestat (MK-8931) / Merck (MSD)
Trial primary completion date: EPOCH: An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) (clinicaltrials.gov) - Mar 14, 2017
P2/3, N=2221, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Mar 2017
- | Trial completion: ICTUS: Transient Global Amnesia (TGA). Exploratory Study of the Default Mode Network During the Acute Phase (clinicaltrials.gov) - Mar 14, 2017
P=N/A, N=43, Completed, Sponsor: University Hospital, Toulouse
Trial primary completion date: Jun 2017 --> Mar 2017 Recruiting --> Completed
- | isoflurane / Generic mfg.
Trial completion, Trial primary completion date: Reconstructing Consciousness and Cognition (clinicaltrials.gov) - Mar 14, 2017
P=N/A, N=60, Completed, Sponsor: University of Michigan
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2015
- | PF-02545920 / Pfizer
Trial termination: Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 (clinicaltrials.gov) - Mar 13, 2017
P2, N=188, Terminated, Sponsor: Pfizer
Recruiting --> Terminated; Study terminated on 15DEC2016 due to study A8241021 showing no significant difference on primary endpoint between PF-02545920 & placebo. No safety concerns.